Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

PRIM-TECH3R Preclinical in vitro Models for the Replacement, Reduction and Refinement of Mouse Models in Preclinical Studies (PRIM-TECH3R)

Coordinator
Infrafrontier Eric, Germany
Runs
1 April 2025 to 31 March 2028
Status
Running
EU funding
€9.0m
Total cost
€9.0m
Partners
20 organisations in 11 countries
Type
Research and Innovation Action
Grant agreement
101188158

What the project is doing

In the project's own words, from its summary on CORDIS.

The use of mouse models in biomedical research has been pivotal in understanding human diseases due to their genetic and physiological similarities to humans. However, concerns on ethics and translatability have prompted a shift towards alternative methods such as complex in vitro models (CIVMs). PRIM-TECH3R addresses this shift by leveraging advanced technologies to develop reliable mouse and human CIVMs for preclinical studies, aiming to reduce and refine the use of animal models.

Through standardised protocols and robust validation procedures, the project will create state-of-the-art in vitro models from mouse disease models, complementing existing in vivo models. This initiative aligns with EU policy objectives and societal demands to address phasing out of animal testing in biomedical research. The project will establish a comprehensive repository of preclinical resources, ensure open access, and foster collaboration between research infrastructures and the biomedical industry.

Training programmes will equip personnel with the necessary skills to provide CIVMs to the research community. By achieving these objectives, PRIM-TECH3R aims to advance the state-of-the-art in research infrastructures, facilitate industrial exploitation, and contribute to transformative changes in biomedical research practices.

Who is involved

OrganisationCityCountryRole
Infrafrontier EricNeuherbergGermanyCoordinator
Biobanks and Biomolecular Resources Research Infrastructure Consortium (bbmri-Eric)GrazAustriaParticipant
Veterinaermedizinische Universitaet WienWienAustriaParticipant
Fyziologicky Ustav Akademie Ved Ceske Republiky Verejna Vyzkumna Instituce (vvi)Praha 4CzechiaParticipant
Ustav Molekularni Genetiky Av Cr V.v.i.Praha 4CzechiaParticipant
European Molecular Biology LaboratoryHeidelbergGermanyThird party
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyParticipant
Aarhus UniversitetAarhus CDenmarkParticipant
Biomedcode Ellas Anonimi Eteria Epistimonikis Kai Texnologikis Erevnas Kai Emborikis Ekmetallefsis Epharmogon IatrikisVariGreeceParticipant
Euro-Bioimaging EricTurkuFinlandParticipant
Finnadvance OyHelsinkiFinlandParticipant
Oulun YliopistoOuluFinlandParticipant
Centre Europeen De Recherche En Biologie Et En MedecineIllkirch CedexFranceParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Consiglio Nazionale Delle RicercheRomaItalyParticipant
Academisch Ziekenhuis GroningenGroningenNetherlandsThird party
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek ZiekenhuisAmsterdamNetherlandsParticipant
Karolinska InstitutetStockholmSwedenAssociatedpartner
United Kingdom Research and InnovationSwindonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI